Pharmaceuticals company Dishman Carbogen Amcis announced Q2FY25 results Net Revenue at Rs 7,890.4 million in Q2FY25 up by 34.5% YoY mainly due to increase in commercial sales in the CRAMS segment in Switzerland and India. Carbogen Amcis AG – CRAMS revenue increased by 51.7% YoY in Q2FY25 primarily due to higher commercial sales and also rollover of certain shipment which got pushed to Q2 from Q1FY25. Carbogen Amcis BV– Cholesterol and Vitamin D analogues revenue decreased by 35.7% YoY in Q2FY25 primarily due to lower sales of Cholesterol SF on account of lower margin realizations. DCAL India – NCE APIs and Intermediates revenue increased by 36.9% YoY in Q2FY25 primarily due to increase in commercial sales from Bavla site. DCAL India – Quats & Generics revenue decreased by 20.8% YoY in Q2FY25 primarily due to slowdown in the agrochemical sector. EBITDA Margin at 18.8% in Q2FY25 compared to 10.8% in Q2FY24 due to: Increase in operating margins in CARBOGEN AMCIS – CRAMS segment from 12.2% to 19.7% due to higher volume of commercial sales. Increase in operating margins at Carbogen Amcis BV from 10.1% to 14.7% due to higher sales of vitamin D analogues with higher margins. Increase in operating margins at DCAL India - NCE APIs & Intermediates to 13.9% compared to negative margins in Q2FY24 due to increase in operations in Bavla site. Net Debt excluding lease liabilities was CHF 173 million as on September 30, 2024. Capital expenditure for H1FY25 was approximately USD 15.9 million. Result PDF
Pharmaceuticals firm Dishman Carbogen Amcis announced Q1FY23 Result : Net Revenue at Rs 5,406.1 mn in Q1 FY23 down by 1.8% YoY mainly on account of lower revenues from Netherlands business. Dishman Carbogen Amcis - NCE APIs and Intermediates revenue increased by 91.9% YoY primarily due to: Increased supplies of APIs and intermediates from Bavla site driven by successful customer audits. Dishman Carbogen Amcis - Quats and Generics revenue increased by 7.1% YoY primarily due to: Increased demand for these products especially in the exports market driven by exceptional operational performance by Naroda site. Carbogen Amcis - CRAMS revenue increased by 3.0% YoY primarily due to: Higher Development revenue comprising 70% of the total revenue for the quarter. Carbogen Amcis - Cholesterol and Vitamin D analogues revenue decreased by 46.0% YoY primarily due to: Carbogen Amcis BV’s Q1FY22 revenue was almost 38% of the total year’s revenue, thus extremely front ended, which is not the case this year. One of the customers last year had stocked up huge amount of inventory in June quarter. EBITDA Margin at 16.3% in Q1 FY23 compared to 18.3% in Q1 FY22 due to: Higher energy costs and higher raw material costs impacted the cost base significantly in Carbogen Amcis BV in the first quarter as compared to last year same quarter. Higher logistics costs has also impacted the cost base globally. One time FX loss impact approximately Rs. 9.00 crores as part of “Other Expenses” Result PDF
Pharmaceuticals firm Dishman Carbogen Amcis declares Q4FY22 result: Net Revenue at Rs 5,689.9 mn in Q4 FY22 up by 7.5% YoY CRAMS revenue increased by 15.9% YoY primarily due to: CRAMS India revenue increased by 114.0% due to continuous increase in commercial supplies from India. Marketable Molecules revenue decreased by 15.3% YoY primarily due to: Carbogen Amcis BV revenue decreased by 13.0% on account of lower sales of Vitamin D analogues Others revenue decreased by 17.7% due to lower sales of quats and intermediates EBITDA Margin at 3.9% in Q4 FY22 compared to 16.7% in Q4 FY21 due to: CGAM revenues were driven hugely by lower margin development revenues. One-time provisions also hit the margins adversely Power and fuel and logistics costs increased across all entities Increased costs shall be passed on to customers once the contracts/orders are renegotiated, hence there is a timing lag. Net Debt excluding lease liabilities was USD 122.7 mn as on March 31, 2022 (USD 121.9 mn as on December 31, 2021). Capital expenditure for Q4 FY22 was approximately USD 9.4 mn and for full year FY22 was approximately USD 61.2 mn Construction of the future dedicated manufacturing building for a Japanese Client for a novel oncology drug linker is progressing, this is well aligned with Customer program. Some advanced intermediated for a US customer has been out-licensed to other US customers We currently run 17 phase III projects, 5 of them are in the very final stage. These projects span therapeutic areas such as antibacterial infection, lymphoma, multiple myeloma, myeloid leukemia, hypersimplex and gastric related disease. 1 additional early phase III project has moved into the late phase arena during Q4 FY2021. Our highly complex GMP precursor for a commercial oncology product for a Japan based client will be manufactured on a yearly basis by CGAM. The flow of inquiries has been strong and consistent over last fiscal. In Europe, the Development Pipeline stands at CHF 106.1 mn as of March 31st , 2022 Result PDF